
To evaluate the zzso characterize the zzso and determine the zzso dose of zzso administered once every 4 zzso 

Patients with advanced solid tumors received escalating doses of zzso as an zzso push every 4 zzso zzso studies were performed with the first treatment zzso 

zzso eligible patients received a total of 54 courses of zzso at doses ranging from zzso to 1 zzso zzso toxicity of zzso was seen in 2 of 4 patients treated at the 1 zzso dose zzso zzso toxicity was generally mild with maximum toxicity being zzso grade 2 per National Cancer Institute Common zzso zzso No objective responses were seen in the 19 eligible zzso An zzso zzso was used to determine zzso plasma zzso The terminal elimination zzso was 140 zzso at the recommended Phase II zzso The area under the concentration time curve increased in proportion to administered dose, and the clearance remained constant over the dose range zzso zzso analysis demonstrated relationships between dose and area under the concentration with cycle 1 zzso zzso including absolute zzso and zzso zzso 

zzso administered every 4 weeks as an zzso push is well tolerated with zzso toxicity of zzso The zzso dose (and recommended Phase II zzso is zzso zzso administered once every 4 zzso 

